A guideline has been issued that outlines the use of 3-D computed tomography-based radiation therapy planning and volumetric image guidance to more effectively treat pediatric Hodgkin lymphoma and to reduce the radiation dose to normal tissue, thus decreasing the risk of late side effects.
The International Lymphoma Radiation Oncology Group has issued a guideline that outlines the use of 3-D computed tomography-based radiation therapy planning and volumetric image guidance to more effectively treat pediatric Hodgkin lymphoma and to reduce the radiation dose to normal tissue, thus decreasing the risk of late side effects. The guideline will be published in the March-April issue of Practical Radiation Oncology, the clinical practice journal of the American Society for Radiation Oncology.
Historically, pediatric Hodgkin lymphoma patients were treated with the same chemotherapy and radiation regimens as adults with Hodgkin lymphoma, which potentially exposes their young, still-growing bodies to more treatment than necessary. Previous radiation therapy guidelines for pediatric Hodgkin lymphoma have focused on 2-D imaging and bony landmarks to define dose volumes for radiation therapy treatment, and treated large volumes of normal tissue in part because of uncertainty about which lymph node areas were involved.
Link to the complete article in ScienceDaily:
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More